Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Semaglutide & Adiposity / Obesity

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

FDA status

In the context of Semaglutide & Adiposity / Obesity, semaglutide is FDA‑approved specifically for the treatment of Adiposity / Obesity in indicated adult patients, i.e., for chronic weight management (2, 3).

EMA status

Semaglutide is EMA‑approved specifically for the treatment of obesity/adiposity in indicated adult patients in the European Union (4, 5).

Clinical Data

The randomized, double-blind, placebo-controlled clinical phase III treatment trial, identified as NCT05035095, demonstrated that in adults who are overweight or obese but do not have typ…

References (Sources)

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
O'Neil et al. 2018 the lancet 392: 637-649
Once-Weekly Semaglutide in Adults with Overweight or Adiposity/Adiposity/Obesity
Wilding et al. 2021 N Engl J Med 384: 989-1002
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Knop et al. 2023 The Lancet 402(10403): 705-719
Semaglutide
Kommu & Whitfield 2026 In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing
Semaglutide 2.4 mg once a week in adults with overweight or adiposity/obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase III trial
Davies et al., 2021 Lancet 397: 971-984
Semaglutide for the treatment of overweight and obesity: A review
Bergmann et al. 2023 Diabetes Obes Metab 25(1): 18-35
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Links

https://web.archive.org/web/20210604235421/https:/www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014)
https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy)